The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients
about
Cost of treatment in a US commercially insured, HIV-1-infected populationBurden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisPrevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers)Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialLong-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.Characteristics and genotype profiles of antiretroviral-naïve patients entering a Southern US HIV outpatient clinic 2009-2012.Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical triProfile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats.Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013
P2860
Q28539139-89BD90AE-29DE-428F-9D7E-24DF75AE54EEQ33988153-FC3164EF-C5DC-4BE1-A01D-23CCD0DE9C1CQ34619859-4EC848C8-7725-49AD-99F8-47AD7E9DD4E6Q35056873-C8C19AF5-21FE-4D32-B601-5EB4C6B7246EQ35124860-66C0FF66-6367-42E8-924B-D9BCB486DE67Q37157278-D442F20A-E8FD-490C-85E8-78ABBA6E747BQ38504434-B1FA3827-DF0F-4A37-B2D3-B2387C457766Q38928255-4A9E4C68-722F-42C9-99EC-044C9CBDC4C6Q40215329-213157CB-9DDE-4B54-B4ED-9C4FBEF5D500Q40708931-164BCD57-DB6B-4FD3-A75B-D744DEB97837Q45961010-FDAFA715-629D-46F7-B82C-D5682927E899Q56911534-3A6AAA58-1ADA-499A-BF9D-3AA49AE3B523
P2860
The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The prevalence of transmitted ...... mpact in HIV-infected patients
@ast
The prevalence of transmitted ...... mpact in HIV-infected patients
@en
The prevalence of transmitted ...... mpact in HIV-infected patients
@nl
type
label
The prevalence of transmitted ...... mpact in HIV-infected patients
@ast
The prevalence of transmitted ...... mpact in HIV-infected patients
@en
The prevalence of transmitted ...... mpact in HIV-infected patients
@nl
prefLabel
The prevalence of transmitted ...... mpact in HIV-infected patients
@ast
The prevalence of transmitted ...... mpact in HIV-infected patients
@en
The prevalence of transmitted ...... mpact in HIV-infected patients
@nl
P2093
P2860
P3181
P1433
P1476
The prevalence of transmitted ...... mpact in HIV-infected patients
@en
P2093
Alexandra Khachatryan
Jennifer Stephens
Katherine Nedrow
Richard Chambers
Seema Haider
Sonya J Snedecor
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0072784
P407
P577
2013-01-01T00:00:00Z